SEC Comment Letter 0000000000-23-006530 to Estrella Immunopharma, Inc. (ESLA, ESLAW) (CIK 0001844417) (ESLA)

Estrella Immunopharma, Inc. (ESLA, ESLAW) (CIK 0001844417)
Date: June 16, 2023 · CIK: 0001844417 · Accession: 0000000000-23-006530

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40608

Date

June 16, 2023

Author

Weiguang Yang

Form

UPLOAD

Company

Estrella Immunopharma, Inc. (ESLA, ESLAW) (CIK 0001844417)

Letter

United States securities and exchange commission logo June 16, 2023 Weiguang Yang Co-Chief Executive Officer TradeUP Acquisition Corp. 437 Madison Avenue, 27th Floor New York, NY 10022 Re:TradeUP Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed May 25, 2023, as amended File No. 001-40608 Dear Weiguang Yang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Er Arila Zhou

Show Raw Text

United States securities and exchange commission logo
June 16, 2023
Weiguang Yang
Co-Chief Executive Officer
TradeUP Acquisition Corp.
437 Madison Avenue, 27th Floor
New York, NY 10022
Re:TradeUP Acquisition Corp.
Preliminary Proxy Statement on Schedule 14A
Filed May 25, 2023, as amended
File No. 001-40608
Dear Weiguang Yang:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Er Arila Zhou

SecProbe.io